NASDAQ:PDSB

PDS Biotechnology (PDSB) Stock Forecast, Price & News

$5.05

+0.02 (+0.40%)

(As of 09/29/2023 ET)

Compare

Today's Range: $4.88
▼
$5.10
50-Day Range: $4.80
▼
$6.40
52-Week Range: $2.89
▼
$13.65

Volume: 486,708 shs
Average Volume: 317,363 shs
Market Capitalization: $155.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

PDS Biotechnology MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 236.6% Upside
$17.00 Price Target
Short Interest: Bearish
14.80% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.02
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.54) to ($1.72) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

885th out of 970 stocks

Pharmaceutical Preparations Industry

416th out of 449 stocks

3.5

Analyst's Opinion

Consensus Rating
PDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, PDS Biotechnology has a forecasted upside of 236.6% from its current price of $5.05.
Amount of Analyst Coverage
PDS Biotechnology has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
14.80% of the outstanding shares of PDS Biotechnology have been sold short.
Short Interest Ratio / Days to Cover
PDS Biotechnology has a short interest ratio ("days to cover") of 7.9.
Change versus previous month
Short interest in PDS Biotechnology has recently increased by 6.53%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
PDS Biotechnology does not currently pay a dividend.
Dividend Growth
PDS Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PDSB.

2.8

News and Social Media Coverage

News Sentiment
PDS Biotechnology has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.
Search Interest
8 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.
MarketBeat Follows
6 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PDS Biotechnology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 10.00% of the stock of PDS Biotechnology is held by insiders.
Percentage Held by Institutions
Only 25.78% of the stock of PDS Biotechnology is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.54) to ($1.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PDS Biotechnology is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PDS Biotechnology is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PDS Biotechnology has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About PDS Biotechnology (NASDAQ:PDSB) Stock

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

PDSB Price History

30 days | 90 days | 365 days | Advanced Chart

PDSB Stock News Headlines

September 30, 2023 | americanbankingnews.com

HC Wainwright Reaffirms "Buy" Rating for PDS Biotechnology (NASDAQ:PDSB)

September 26, 2023 | finance.yahoo.com

PDS Biotech to Present at the LD Micro Main Event XVI

September 30, 2023 | Altimetry (Ad)

WARNING: Seven millionaires to trigger sudden market panic?

The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.

September 25, 2023 | finance.yahoo.com

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

September 22, 2023 | americanbankingnews.com

PDS Biotechnology (NASDAQ:PDSB) Stock Rating Reaffirmed by HC Wainwright

September 20, 2023 | finance.yahoo.com

PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

September 20, 2023 | finance.yahoo.com

PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

September 13, 2023 | finance.yahoo.com

PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023

September 30, 2023 | Altimetry (Ad)

WARNING: Seven millionaires to trigger sudden market panic?

September 6, 2023 | finance.yahoo.com

PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

September 6, 2023 | finance.yahoo.com

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference

September 3, 2023 | fool.com

PDS Biotechnology (NASDAQ: PDSB)

August 16, 2023 | finance.yahoo.com

PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting

August 15, 2023 | markets.businessinsider.com

PDS Biotechnology (PDSB) Gets a Buy from Noble Financial

August 15, 2023 | finance.yahoo.com

Q2 2023 PDS Biotechnology Corp Earnings Call

August 14, 2023 | seekingalpha.com

The Prognosis For PDS Biotechnology

August 14, 2023 | finanznachrichten.de

PDS Biotechnology Corporation: PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

August 14, 2023 | finance.yahoo.com

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

August 14, 2023 | finance.yahoo.com

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

August 14, 2023 | msn.com

PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study

August 11, 2023 | benzinga.com

PDS Biotechnology Earnings Preview

August 7, 2023 | finance.yahoo.com

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

August 2, 2023 | finance.yahoo.com

PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023

July 26, 2023 | benzinga.com

PDS Biotechnology – Top-Line Data From Its Lead Candidate Points To Promising Future For This Company

July 25, 2023 | finance.yahoo.com

PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023

July 17, 2023 | finance.yahoo.com

PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023

July 11, 2023 | finance.yahoo.com

PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301

See More Headlines

Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PDSB Company Calendar

Last Earnings: 8/14/2023
Today: 9/30/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PDSB
CUSIP: N/A
CIK: 1472091
Web: www.pdsbiotech.com
Phone: (800) 208-3343
Fax: 908-790-1212
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.00
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +236.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,850,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -116.11%
Return on Assets: -67.24%

Debt

Debt-to-Equity Ratio: 0.72
Current Ratio: 8.02
Quick Ratio: 8.02

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.55 per share
Price / Book: 3.26

Miscellaneous

Outstanding Shares: 30,868,000
Free Float: 27,781,000
Market Cap: $155.88 million
Optionable: Not Optionable
Beta: 1.93

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Frank K. Bedu-Addo Ph.D. (Age 58)
Pres, CEO & Director
Comp: $854.1k

Mr. Matthew C. Hill CPA (Age 54)
CFO, Principal Financial & Accounting Officer
Comp: $504.09k

Ms. Lauren V. Wood M.D. (Age 63)
Chief Medical Officer
Comp: $568.5k

Dr. Joe J. Dervan
VP of R&D

Dr. Gregory L. Conn Ph.D. (Age 68)
Chief Scientific Officer

Ms. Deanne Randolph
VP of Commercial Devel. & Head of Investor Relations

Mr. Spencer Brown J.D. (Age 53)
Sr. VP & Gen. Counsel

Ms. Nathalie Riebel
Sr. VP of Clinical Operations

Mr. Sanjay Zaveri
Sr. VP of Bus. Devel.

Ms. Janetta Trochimiuk (Age 60)
Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PDSB Stock - Frequently Asked Questions

Should I buy or sell PDS Biotechnology stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PDSB shares.
View PDSB analyst ratings or view top-rated stocks.
What is PDS Biotechnology's stock price forecast for 2023?: 3 Wall Street research analysts have issued 1 year price targets for PDS Biotechnology's stock. Their PDSB share price forecasts range from $12.00 to $21.00. On average, they predict the company's share price to reach $17.00 in the next year. This suggests a possible upside of 236.6% from the stock's current price.
View analysts price targets for PDSB or view top-rated stocks among Wall Street analysts.
How have PDSB shares performed in 2023?: PDS Biotechnology's stock was trading at $13.20 at the start of the year. Since then, PDSB stock has decreased by 61.7% and is now trading at $5.05.
View the best growth stocks for 2023 here.
When is PDS Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our PDSB earnings forecast.
How were PDS Biotechnology's earnings last quarter?: PDS Biotechnology Co. (NASDAQ:PDSB) issued its earnings results on Monday, August, 14th. The company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37).

What other stocks do shareholders of PDS Biotechnology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PDS Biotechnology investors own include Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Boxlight (BOXL), Otonomy (OTIC), Bionano Genomics (BNGO), CymaBay Therapeutics (CBAY), Cerecor (CERC), Enterprise Products Partners (EPD) and Evofem Biosciences (EVFM).
What is PDS Biotechnology's stock symbol?: PDS Biotechnology trades on the NASDAQ under the ticker symbol "PDSB."
How do I buy shares of PDS Biotechnology?: Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is PDS Biotechnology's stock price today?: One share of PDSB stock can currently be purchased for approximately $5.05.
How much money does PDS Biotechnology make?: PDS Biotechnology (NASDAQ:PDSB) has a market capitalization of $155.88 million. The company earns $-40,850,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.
How can I contact PDS Biotechnology?: PDS Biotechnology's mailing address is 25B Vreeland Road, Florham Park NJ, 07932. The official website for the company is www.pdsbiotech.com. The company can be reached via phone at (800) 208-3343, via email at ir@edgetherapeutics.com, or via fax at 908-790-1212.

This page (NASDAQ:PDSB) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial